Narayanan R. is Head of Product Strategy and Management for the TCS ADD™ suite of platforms at Tata Consultancy Services (TCS), with over two decades of deep domain expertise in Clinical Development and Pharmacovigilance. In this role, he owns the end‑to‑end product vision, roadmap, and market adoption of TCS ADD’s AI‑driven platforms supporting clinical trials, safety, and regulatory operations globally.
Across his career, Narayanan has worked closely with many of the world’s top 20 pharmaceutical companies, incubating innovative technologies and delivering and scaling enterprise platforms across clinical development and pharmacovigilance business functions.
Currently, he is focused on agentic AI and AI‑native product architectures - designing governed, explainable, and compliant autonomous agents that orchestrate complex scientific and operational processes at scale. His leadership uniquely combines deep life‑sciences credibility with modern AI product thinking, enabling trusted, production‑grade adoption in highly regulated environments.
There are plenty of AI pilots in place, and an increasing number of pharmacovigilance use cases are now moving into scaled operations. Yet the real opportunity lies beyond automation. In this session, we share our experience of introducing and operationalizing AI across pharmacovigilance, drawing on lessons learned from multiple generations of technology. We will discuss the principles required to make AI trustworthy, human-centric, and enterprise-ready, including governance, human oversight, and continuous learning. Attendees will gain practical insights into opportunities, challenges, common pitfalls, and the key foundations needed to translate AI innovation into measurable patient safety outcomes.